HealthAxis and COPE Health Solutions Form Strategic Partnership to Enhance Value-Based Care

HealthAxis, a leader in healthcare administration technology, has partnered with COPE Health Solutions (CHS), a specialist in value-based care and population health management. This strategic collaboration aims to provide comprehensive, end-to-end solutions for health plans and providers engaged in value-based…

Read MoreHealthAxis and COPE Health Solutions Form Strategic Partnership to Enhance Value-Based Care

DeepCure to Present In Vivo Data on DC-9476, a Superior BRD4 Inhibitor for Rheumatoid Arthritis

DeepCure, a therapeutics company leveraging AI to discover innovative drugs for inflammation and immune diseases, today announced that it will present data demonstrating that its selective BRD4 (BD2) inhibitor, DC-9476, is more effective than anti-TNF-α treatment in a collagen antibody-induced…

Read MoreDeepCure to Present In Vivo Data on DC-9476, a Superior BRD4 Inhibitor for Rheumatoid Arthritis

AI Software for Breast Arterial Calcification Scoring Predicts Cardiovascular Outcomes in Women, Study Shows

CureMetrix® has announced a new peer-reviewed study confirming the effectiveness of its investigational AI-enabled software for automated breast arterial calcification (BAC) detection in mammograms. This technology can inform personalized risk predictions for mortality and cardiovascular disease in women. The study…

Read MoreAI Software for Breast Arterial Calcification Scoring Predicts Cardiovascular Outcomes in Women, Study Shows

Digbi Health to Unveil Study on Gut Microbiome and GLP-1 Production at 2024 Obesity Society Conference

Digbi Health, a leader in Precision Biology and personalized healthcare, has been invited to present a groundbreaking study at the Obesity Society Conference. The research highlights how the Digbi Health program effectively modifies the gut microbiome to boost the body’s…

Read MoreDigbi Health to Unveil Study on Gut Microbiome and GLP-1 Production at 2024 Obesity Society Conference

PHC Showcases LiCellGrow Automated Cell Culture Prototype with In-Line Monitoring at Regenerative Medicine JAPAN 2024

PHC to Showcase LiCellGrow Prototype for Automated Cell Culture at Regenerative Medicine JAPAN 2024 PHC Corporation’s Biomedical Division will present the prototype of “LiCellGrow,” an automated cell culture device designed for developing cell medicine manufacturing processes, at the Regenerative Medicine…

Read MorePHC Showcases LiCellGrow Automated Cell Culture Prototype with In-Line Monitoring at Regenerative Medicine JAPAN 2024

Fresenius Kabi and Formycon Gain FDA Approval for Biosimilar Otulfi™ (ustekinumab-aauz)

Fresenius Kabi, part of Fresenius and specializing in biopharmaceuticals, clinical nutrition, and medical technologies, along with Formycon AG, an independent developer of biosimilars, has announced FDA approval for Otulfi™ (ustekinumab-aauz), a biosimilar referencing Stelara® (ustekinumab). Otulfi™ is approved for treating…

Read MoreFresenius Kabi and Formycon Gain FDA Approval for Biosimilar Otulfi™ (ustekinumab-aauz)

Repare Therapeutics Presents Phase 1 Data on Camonsertib and Radiotherapy at ASTRO Annual Meeting

Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, today shared data showcasing the clinical benefits of camonsertib, a promising oral small molecule ATR inhibitor, used in combination with palliative radiation for treating metastatic tumors with an ataxia-telangiectasia-mutated (ATM)…

Read MoreRepare Therapeutics Presents Phase 1 Data on Camonsertib and Radiotherapy at ASTRO Annual Meeting